AirLeaf - Bronchiectasis Clinical Trial


The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis.

Trial Status
Trial Phase
Phase 2 Drug Trial
Trial contact details
Contact Person
RIO Clinical Trials Team
What you need to know

Who can take part?

  • This study is open to adults (≥18 and ≤85 years) with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations).
  • History of pulmonary exacerbations requiring antibiotic treatment in the past 12 months

What is involved for you?

  • Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day.
  • Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff.
  • The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.

Trial dates

October 2022 to October 2023

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|